Sunday, June 22, 2014

GM Spliced in Death & Birth of GM Human Being Begins ~TO CONTROL POPULATIONS

FDA is on the way to approve 100% GM created human babies. Also, death a certainty without a special doctor prescribed antibiotic is being spliced into flies. Death in 100% of females before adult stage, but males still live and do their damage to sheep.

"As mainstream society inches increasingly further away from the natural order of things, some scientists are busy hatching new methods of human reproduction that employ the same gene-altering techniques used by biotechnology companies like Monsanto. And according to new reports, the U.S. Food and Drug Administration (FDA) is fully on board with this brave new agenda, having recently met to discuss the future of what the mainstream media is now referring to as genetically modified (GM) human beings."
This article is more hype then anything else but, it seems to be the beginning of making it happen though...

They have a special new office and committee to address the issues at the FDA.
"OCTGT is interested in obtaining broad public input before finalizing the guidance" Have you ever heard their broadcasts about this? To get your opinion? And what is this office at the FDA...and what does it do? "this draft guidance does not apply to human cell, tissue, and cellular-and tissue-based products (HCT/Ps) regulated solely under section 361 of the PHS Act "
Since Monsanto has taken over our government people need to realize how they lie...
The same PR story is played over and over again...
That is a LIE and a COVER-STORY
"To Save the World"...
Idiots! That's my line! How dare you!

"The comment period for this draft guidance will close on May 9, 2014, after which the Office of Cellular, Tissue, and Gene Therapies (OCTGT) will consider the comments and publish a final guidance. OCTGT is interested in obtaining broad public input before finalizing the guidance, and discussion at this Advisory Committee meeting is important to facilitate that process.

The design of early-phase clinical trials of cellular and gene therapy (CGT) products often differs from the design of clinical trials for other types of pharmaceutical products. Differences in trial design are necessitated by the distinctive features of these products, including product characteristics, manufacturing considerations, and preclinical considerations. By issuing this draft guidance, OCTGT is endeavoring to provide sponsors of INDs for CGT products with recommendations that can assist them in designing their early-phase clinical trials. The intent is not to set forth any new requirements on sponsors of CGT INDs; rather, the objective is to provide information and perspective that will improve the early development of CGT products and facilitate sponsors’ interactions with OCTGT. 

The draft guidance begins with a description of distinctive features of CGT products that influence clinical trial design. The document then provides recommendations with respect to clinical trial design, including early-phase trial objectives, choosing a study population, using a control group and blinding, dose selection, treatment plans, monitoring, and follow-up. These recommendations focus on aspects of clinical trial design that are often different for CGT products than for other types of pharmaceutical products. Finally, the draft guidance encourages prospective sponsors to communicate with OCTGT review staff regarding their IND submission, and references are provided for additional guidance on submitting an IND to OCTGT. 

The scope of this draft guidance is limited to CGT products regulated by OCTGT as biological products under section 351(i) of the Public Health Service (PHS) Act. Thus, this draft guidance does not apply to human cell, tissue, and cellular-and tissue-based products (HCT/Ps) regulated solely under section 361 of the PHS Act or to the therapeutic biological products for which the Center for Drug Evaluation and Research (CDER) has regulatory responsibility. 

Dr. Max Scott, professor of entomology at NC State, and his research team genetically modified lines of female Australian sheep blowflies (Lucilia cuprina) so that they required doses of tetracycline in order to live. Female blowflies that did not receive the antibiotic died in the late larval or pupal stages, before reaching adulthood. Several genetically modified lines lacking tetracycline showed 100 percent female deaths.
Scott says that the gene construct responsible for lethality in antibiotic-free diets is female-specific. Interestingly and unexpectedly, the genetically modified female larvae containing the tetracycline lethality genes also took on a crimson color due to overexpression of the linked red fluorescent protein “marker gene.” This allows scientists to tell which larvae will be females and which will be males.

“Overexpression of the gene responsible for the reliance on tetracycline also seems to overexpress this marker gene,” Scott says.

Since the females will die when not provided tetracycline in their diets, the males can be separated out in the larval stage. This is essential for a “male-only” genetic control program to reduce blowfly populations, Scott says, as fertile males would pass the lethality construct on to female offspring, which would die in the absence of tetracycline. Male larval offspring, however, would still be dangerous to livestock.
If this isn't freaking you out...
Check your underwear...
You may be unaware!

No comments:

Post a Comment